- Tracking Exercise by Steps or Minutes? Study Finds Either Method Boosts Health
- Stomach Paralysis Risk May Rise in People Taking Ozempic and Similar Drugs
- In a Shift, Pediatricians’ Group Says Breastfeeding Safe When HIV-Positive Mom Is Properly Treated
- Fertility Treatments Safe for Breast Cancer Survivors With Cancer-Linked Genes
- 1 in 4 Parents Say Their Teen Drinks Caffeine Daily
- New Blood Test Could Spot Dangerous Type of Stroke
- Blood Pressure Meds Raise Fracture Risks for Those in Nursing Homes
- Could Infertility Treatment Raise Postpartum Heart Risks?
- Does It Matter What You Eat or Drink Before Bed?
- Your Allergy Meds Come With Hazards: Be Aware
Cerdelga Approved for Gaucher Disease
Cerdelga (eliglustat) has been approved by the U.S. Food and Drug Administration to treat type 1 Gaucher disease, a rare inherited disorder caused by the body’s insufficient production of a key enzyme.
Lack of the enzyme glucocerebrosidase causes fatty deposits in the spleen, liver and bone marrow. Symptoms include liver and spleen enlargement, anemia, low blood platelets and bone problems, the FDA said in a news release.
Gaucher affects about 6,000 people in the United States. Cerdelga is a gelatin capsule that’s designed to slow the body’s production of abnormal fatty deposits.
Cerdelga was evaluated in clinical studies involving 199 people with type 1 Gaucher disease. The most common side effects were fatigue, headache, nausea, diarrhea, and pain of the back, arms and legs, and upper abdomen.
Cerdelga is produced by Genzyme, based in Cambridge, Mass.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.